F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma

We evaluated the prognostic significance of standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) obtained by F‐18 FDG PET/CT (PET/CT) in patients with diffuse large B‐cell Lymphomas (DLBCL) presenting intermediate IPI score.

[1]  B. Beuthien-Baumann,et al.  Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.

[2]  U. Tateishi,et al.  SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma , 2010, Leukemia & lymphoma.

[3]  L. Pace,et al.  Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. , 2010, Radiology.

[4]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[5]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Jaiyesimi,et al.  Correlating Metabolic Activity with Cellular Proliferation in Follicular Lymphomas , 2009, Molecular Imaging and Biology.

[7]  M. Baccarani,et al.  Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.

[8]  L. Dušek,et al.  Standardised uptake value of 18F‐FDG on staging PET/CT in newly diagnosed patients with different subtypes of non‐Hodgkin’s lymphoma , 2011, European journal of haematology.

[9]  J. Armitage,et al.  Positron emission tomographic scans in lymphoma: convention and controversy. , 2012, Mayo Clinic proceedings.

[10]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[11]  A. Serafini,et al.  FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.

[12]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Baccarani,et al.  Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation , 2005, Nuclear medicine communications.

[14]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Dong Soo Lee,et al.  Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma , 2013, Cancer.

[16]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[17]  J. Choi,et al.  The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma , 2012, American journal of hematology.

[18]  A. Rosenwald,et al.  Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma – analyses of cases from two prospective randomized clinical trials , 2009, Haematologica.

[19]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[20]  R. Gascoyne,et al.  Clinical Trials and Observations , 2007 .

[21]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[22]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[23]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[24]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Oki,et al.  High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma , 2011, International journal of hematology.

[26]  S. Hee,et al.  High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  M. Shipp.  Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? , 1994, Blood.

[28]  J. Briones,et al.  Epidemiology of lymphoid malignancies: last decade update , 2013, SpringerPlus.

[29]  L. Pace,et al.  Assessment of metabolic activity by PET‐CT with F‐18‐FDG in patients with T‐cell lymphoma , 2010, British journal of haematology.

[30]  H. Tu,et al.  SUV on Dual-Phase FDG PET/CT Correlates With the Ki-67 Proliferation Index in Patients With Newly Diagnosed Non-Hodgkin Lymphoma , 2012, Clinical nuclear medicine.

[31]  L. Medeiros,et al.  Diffuse Large B-Cell Lymphoma, Not Otherwise Specified , 2013 .

[32]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[33]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. , 2001, Haematologica.

[34]  B. Cheson,et al.  The role of FDG-PET scans in patients with lymphoma. , 2007, Blood.

[35]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[36]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[37]  J. Rowe,et al.  Strikingly high false positivity of surveillance FDG‐PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era , 2013, American journal of hematology.

[38]  L. Ruco,et al.  Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma , 2008, Leukemia & lymphoma.

[39]  L. Specht,et al.  Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake , 2006, Hematological oncology.

[40]  J. Cousar,et al.  Large-cell lymphomas: clinical and prognostic features. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.